key: cord-0913499-3u8uejdk
authors: Nguyen, C.; Yale, K.; Casale, F.; Ghigi, A.; Zheng, K.; Silverberg, J.I.; Mesinkovska, N.A.
title: SARS‐CoV‐2 infection in patients with atopic dermatitis: a cross‐sectional study
date: 2021-06-02
journal: Br J Dermatol
DOI: 10.1111/bjd.20435
sha: ae7bbe28439e7cbd9e73052891845197145b699d
doc_id: 913499
cord_uid: 3u8uejdk

Dear Editor, SARS-CoV-2 disproportionately impacts certain populations with inflammatory conditions which have an elevated risk of respiratory comorbidities.1-3 Additionally, atopic dermatitis (AD) is associated with other atopic diseases, such as allergic rhinitis and asthma, which increases the risk of respiratory infections and predisposes patients to neuropsychiatric disorders.4 There are limited studies evaluating the role of systemic medications on risk of infection.

SARS-CoV-2-positive patients with AD (n = 159) who were taking systemic medications had SARS-CoV-2 infection rates comparable with those not taking systemic medications. This was noted for patients on prednisone (2Á6% vs. 2Á99%, P = 0Á62) and methotrexate (2Á7% vs. 2Á96%, P > 0Á99) ( Table 1) . No patients in the SARS-CoV-2-positive AD cohort were on ciclosporin or dupilumab. Hospitalizations within 2 weeks of a SARS-CoV-2 test (1 week prior or subsequent to testing) were assessed as a marker of infection severity. The hospitalization rate of SARS-CoV-2-positive patients with AD was 13Á8% (n = 22), which was not significantly different from those without AD (19Á3%, n = 1858; P = 0Á085).

Lastly, the mortality rate of SARS-CoV-2-positive patients in the UC CORDS was 2Á1% (n = 203, average age 71 years), and that of SARS-CoV-2-positive patients with AD was 1Á9% (n = 3, average age 82 years). The mortality rate for SARS-CoV-2-positive patients with AD on prednisone was 8% (n = 1), which was not significantly different from those without AD (P = 0Á21).

In this UC CORDS dataset, patients with AD did not have significantly increased risk for SARS-CoV-2 infection, including those on immunomodulatory medications (prednisone or methotrexate). In AD, inflammatory cytokines, such as interleukin-13, can regulate SARS-CoV-2 entry into airway epithelial cells by increasing transmembrane protease serine 2 and decreasing angiotensin-converting enzyme 2 expression, thus decreasing the risk of SARS-CoV-2. 1 Although our study did not have COVID-19-positive patients on dupilumab, other studies have shown that patients with AD treated with dupilumab did not have increased risk of SARS-CoV-2 infection or worsened clinical outcomes. 5,6 These data do not account for the presence of comorbidities such as asthma and/or allergic rhinitis. The overall lower age of patients with AD, compared with those without AD, may account for the observed significant difference in infection rates (average 42 vs. 47 years).

Limitations of this study include the small sample size on systemic medications, lack of data on systemic medication use within the control population, use of tertiary centre data and de-identified data with lack of clinical details including confounding variables (age, body mass index, average medication doses, concurrent medication use) or follow-up. Future studies with identifiable datasets will help better assess this relationship. Understanding the mechanisms underlying SARS-CoV-2 susceptibility are fundamental to develop better guidelines for populations at risk.

Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells

Dupilumab and COVID-19: what should we expect?

European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection and atopic dermatitis

Selected comorbidities of atopic dermatitis: atopy, neuropsychiatric, and musculoskeletal disorders

No evidence of increased risk for coronavirus disease 2019 (COVID-19) in patients treated with dupilumab for atopic dermatitis in a high-epidemic area -Bergamo

Management of adult patients with severe atopic dermatitis treated with dupilumab during COVID-19 pandemic: a single-center real-life experience

California Health creates centralized data set to accelerate COVID-19 research

Funding sources: the project described was supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences

Table 1 Patients with atopic dermatitis (AD) within the University of California COVID Research Data Set who tested positive for SARS-CoV-2 and had been on medication for AD for at least 30 days prior to the SARS-CoV-2 test, compared with patients without AD and patients not on medication, respectively (up to

SARS-CoV-2 positive SARS-CoV-2 hospitalizations a SARS-CoV-2 mortality b